Pfizer Inc. $PFE Stake Boosted by Jackson Hole Capital Partners LLC

Key Points

• Jackson Hole Capital Partners LLC boosted its stake in Pfizer by 13.5%, owning 125,819 shares valued at $3,050,000 by the end of the recent quarter.
• Pfizer's quarterly earnings surpassed expectations, reporting $0.78 EPS and generating $14.65 billion in revenue, up 10.3% from the previous year.
• The company declared a quarterly dividend of $0.43 per share, resulting in an annualized dividend yield of 7.0%, with the payout scheduled for December 1st.

Jackson Hole Capital Partners LLC increased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 13.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 125,819 shares of the biopharmaceutical company's stock after purchasing an additional 14,982 shares during the quarter. Jackson Hole Capital Partners LLC's holdings in Pfizer were worth $3,050,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in PFE. Pacer Advisors Inc. lifted its stake in Pfizer by 856.8% during the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock worth $508,164,000 after purchasing an additional 17,957,928 shares during the last quarter. Amundi lifted its stake in Pfizer by 43.4% during the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock worth $1,265,277,000 after purchasing an additional 15,758,846 shares during the last quarter. Nuveen LLC bought a new position in Pfizer during the first quarter worth $389,861,000. Goldman Sachs Group Inc. lifted its stake in Pfizer by 51.9% during the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock worth $670,407,000 after purchasing an additional 9,041,990 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Pfizer by 0.9% in the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock valued at $13,257,004,000 after buying an additional 4,629,976 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on PFE. Citigroup raised their target price on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Morgan Stanley cut their target price on Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a research note on Friday, October 10th. Wall Street Zen cut Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday, September 28th. UBS Group reiterated a "neutral" rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Weiss Ratings reiterated a "hold (c-)" rating on shares of Pfizer in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $28.13.

Pfizer Price Performance

Shares of PFE opened at $24.68 on Friday. The firm has a market capitalization of $140.29 billion, a price-to-earnings ratio of 13.13, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.17. The stock's fifty day moving average is $24.87 and its 200-day moving average is $24.15.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company's quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer's dividend payout ratio (DPR) is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.